Bladder cancer
Conditions
Interventions
Experimental group:TURBT combined with chemotherapy and immunotherapy
Control group:TURBT combined with chemotherapy
Sponsors
The Seventh Affiliated Hospital of Sun Yat-Sen University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients who are unwilling to accept or cannot tolerate radical cystectomy voluntarily participate in and sign informed consent based on fully understanding the clinical trial; 2. Patients diagnosed with T1 high-grade or T2 bladder cancer; 3. 18-75 years old; 4. The pathological type is urothelial carcinoma; 5. Return to the hospital regularly; 6. Can be followed up for at least one year.
Exclusion criteria
Exclusion criteria: 1. Chemotherapy contraindications (PS score > 1, GFR = 2, peripheral neuropathy, NYHA grade III heart failure or above); 2. Allergic to chemotherapeutic drugs or immunotherapy drugs; 3. Combined with lymph node metastasis or distant metastasis; 4. Pregnant or breastfeeding patients; 5. Combined with other malignant tumors; 6. Combined with radiotherapy, another intravesical instillation therapy except for intraoperative intravesical instillation chemotherapy, or other anti-tumor treatments; 7. Combined with autoimmune diseases or long-term use of immunosuppressive drugs (including prednisone > 10mg/day); 8. Combined with severe cardiovascular, respiratory, liver, and kidney diseases or poor blood sugar control; 9. Combined with mental disorders; 10. Poor compliance; 11. Combined with other clinical and laboratory conditions not suitable to participate in the experiment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pathologic response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival;Overall survival;Incidence of side effects;Quality of life; | — |
Countries
China
Contacts
Public ContactPang Jun
The Seventh Affiliated Hospital of Sun Yat-Sen University
Outcome results
None listed